

Muthiah Vaduganathan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7604998/muthiah-vaduganathan-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291
papers

8,147
citations

40
h-index

82
g-index

345
ext. papers

11,713
ext. citations

8.1
avg. IF

6.86
L-index

#	Paper	IF	Citations
291	Physician Practice Pattern Variations in Common Clinical Scenarios Within 5 US Metropolitan Areas. <i>JAMA Health Forum</i> , 2022 , 3, e214698	2	0
290	Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018.. <i>ESC Heart Failure</i> , 2022 ,	3.7	2
289	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.. <i>ESC Heart Failure</i> , 2022 ,	3.7	1
288	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 432-444	15.1	2
287	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 504-510	15.1	0
286	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.. <i>JACC: Heart Failure</i> , 2022 , 10, 1-11	7.9	0
285	Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7-year nationwide veteran administration analysis. <i>International Journal of Cardiology</i> , 2022 , 346, 30-34	3.2	0
284	Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. <i>American Heart Journal</i> , 2022 , 243, 103-109	4.9	7
283	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 184-197	7.9	4
282	Implementation of Cardiometabolic Centers and Training Programs.. <i>Current Diabetes Reports</i> , 2022 , 1	5.6	
281	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , 2021 , 36, 108101	3.2	2
280	Association of Readmission Penalty Amount with Subsequent 30-Day Risk Standardized Readmission and Mortality Rates Among Patients Hospitalized with Heart Failure: An Analysis of Get With The Guidelines - Heart Failure Participating Centers.. <i>American Heart Journal</i> , 2021 , 246, 1-1	4.9	
279	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
278	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2004-2012	15.1	7
277	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008597	7.6	0
276	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6	0
275	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1635-1654	15.1	9

274	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1587-1598	15.1	3
273	Serum Potassium and Mortality in High-Risk Patients: SPRINT. <i>Hypertension</i> , 2021 , 78, 1586-1594	8.5	1
272	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121008403	7.6	1
271	Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e35-e37	6.4	1
270	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database. <i>JAMA Cardiology</i> , 2021 , 6, 92-96	16.2	6
269	Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk. <i>European Journal of Heart Failure</i> , 2021 , 23, 1002-1008	12.3	9
268	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021 , 143, 949-958	16.7	2
267	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 1583-1594	10.3	5
266	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 1346-1356	12.3	2
265	Biomarker-Based Risk Prediction of Incident Heart Failure in Pre-Diabetes and Diabetes. <i>JACC: Heart Failure</i> , 2021 , 9, 215-223	7.9	12
264	Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. <i>European Journal of Heart Failure</i> , 2021 , 23, 1191-1201	12.3	11
263	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1961-1973	15.1	7
262	Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 374-382	7.9	6
261	Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. <i>Stroke</i> , 2021 , 52, e217-e223	6.7	6
260	Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1280-1284	3.3	2
259	Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 100172-100172	1.9	1
258	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). <i>European Journal of Heart Failure</i> , 2021 , 23, 1499-1511	12.3	13
257	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 2608-2616	3.7	2

256	Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. <i>Journal of General Internal Medicine</i> , 2021 , 36, 2532-2535	4	6
255	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1518-1524	12.3	7
254	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. <i>Heart</i> , 2021 , 107, 1407-1416	5.1	1
253	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. <i>European Journal of Heart Failure</i> , 2021 , 23, 1468-1476	12.3	6
252	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021 , 144, 177-189	16.9	5
251	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007440	5.8	4
250	Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. <i>European Journal of Heart Failure</i> , 2021 , 23, 384-392	12.3	10
249	Trends in Female Authorship: A Bibliometric Analysis of The Annals of Thoracic Surgery. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 1387-1393	2.7	8
248	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021 , 232, 154-163	4.9	3
247	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , 2021 , 8, 26-36	3.7	2
246	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021 , 14, e007492	5.8	5
245	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , 2021 , 9, 1-12	7.9	10
244	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021 , 9, 65-73	7.9	44
243	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021 , 6, 354-357	16.2	3
242	Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure: The ARIC Study. <i>JACC: Heart Failure</i> , 2021 , 9, 179-189	7.9	7
241	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. <i>Heart Failure Reviews</i> , 2021 , 26, 11-21	5	1
240	Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e38-e40	6.4	1
239	Considering dose in pharmacological therapies for heart failure - Authors Reply. <i>Lancet, The</i> , 2021 , 397, 275	40	

238	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021 , 69, 1309-1318	5.6	2
237	Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017. <i>JAMA Network Open</i> , 2021 , 4, e2033994	10.4	8
236	Trends, Management, and Outcomes of Acute Myocardial Infarction Hospitalizations With In-Hospital-Onset Versus Out-of-Hospital Onset: The ARIC Study. <i>Journal of the American Heart Association</i> , 2021 , 10, e018414	6	2
235	Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 848-857	15.1	14
234	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 330-343	15.1	14
233	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021 , 237, 45-53	4.9	2
232	Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization?. <i>Journal of Cardiac Failure</i> , 2021 , 27, 910-912	3.3	
231	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). <i>American Journal of Cardiology</i> , 2021 , 158, 59-65	3	0
230	Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 453-464	15.1	5
229	Marijuana Use and In-Hospital Outcomes After Percutaneous Coronary Intervention in Michigan, United States. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1757-1767	5	0
228	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2775-2784	6.7	2
227	The Intersection of Type 2 Myocardial Infarction and Heart Failure. <i>Journal of the American Heart Association</i> , 2021 , 10, e020849	6	2
226	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , 2021 ,	16.2	4
225	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1027-1030	3.3	
224	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021 , 21, 41	5.6	0
223	Gender Differences in Medicare Payments Among Cardiologists. <i>JAMA Cardiology</i> , 2021 ,	16.2	1
222	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. <i>Progress in Cardiovascular Diseases</i> , 2021 , 68, 97-98	8.5	2
221	Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1242-1253	15.1	1

220	Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with Histories of Bariatric Surgery. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	1
219	Modifiable Risk Factor Burden Among 3 Different Age Groups with Heart Failure. <i>American Journal of Cardiology</i> , 2021 , 156, 150-152	3	
218	Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2021 , 156, 140-142	3	1
217	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veterans Health Administrative Database. <i>CardioRenal Medicine</i> , 2021 , 1-11	2.8	1
216	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. <i>International Journal of Cardiology</i> , 2021 , 323, 188-191	3.2	3
215	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. <i>Circulation: Heart Failure</i> , 2021 , CIRCHEARTFAILURE121009099	7.6	1
214	Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019. <i>Journal of the American Heart Association</i> , 2021 , e022644	6	1
213	Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses. <i>Circulation: Heart Failure</i> , 2020 , 13, e007070	7.6	2
212	Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1647-1658	2.3	6
211	Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients?. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2574-2575	15.1	1
210	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2517-2521	15.1	5
209	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e006758	7.6	6
208	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 280-288	15.1	110
207	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 618-626	7.9	6
206	Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 2524-2526	27.4	81
205	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation</i> , 2020 , 142, 230-243	16.7	19
204	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020 , 43, 1920-1928	14.6	14
203	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. <i>JAMA Cardiology</i> , 2020 , 5, 1182-1190	16.2	27

202	Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. <i>JACC: Heart Failure</i> , 2020 , 8, 640-653	7.9	23
201	Orphan Drug Development in Cardiovascular Medicine. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006509	5.8	2
200	Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper. <i>JACC: Heart Failure</i> , 2020 , 8, 347-358	7.9	27
199	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1644-1656	15.1	23
198	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , 2020 , 5, 714-722	16.2	29
197	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 382, 1653-1659	59.2	1316
196	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020 , 8, 372-381	7.9	25
195	Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , 2020 , 43, e26-e27	14.6	1
194	Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries. <i>JAMA Network Open</i> , 2020 , 3, e200181	10.4	5
193	Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. <i>Circulation: Heart Failure</i> , 2020 , 13, e006623	7.6	13
192	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. <i>JAMA Cardiology</i> , 2020 , 5, 515-521	16.2	7
191	Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). <i>JAMA Cardiology</i> , 2020 , 5, 576-581	16.2	11
190	Running thin: implications of a heparin shortage. <i>Lancet, The</i> , 2020 , 395, 534-536	4.0	7
189	Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 320-332	15.1	47
188	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study. <i>Circulation: Heart Failure</i> , 2020 , 13, e006638	7.6	3
187	Thirty-Day Nonindex Readmissions and Clinical Outcomes After Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 484-491	2.7	5
186	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , 2020 , 125, 1577-1581 ¹		
185	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020 , 41, 2356-2362	9.5	21

184	Cardio-Renal-Metabolic Care Models: Toward Achieving Effective Interdisciplinary Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e007264	5.8	7
183	Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure: A Nationwide Readmissions Database Study. <i>JACC: CardioOncology</i> , 2020 , 2, 710-718	3.8	0
182	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. <i>JACC: Heart Failure</i> , 2020 , 8, 469-480	7.9	16
181	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , 2020 , 396, 121-128	40	133
180	Angioedema in COVID-19. <i>European Heart Journal</i> , 2020 , 41, 3283-3284	9.5	13
179	Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 177-179	4.6	1
178	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 472-485	12.3	28
177	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020 , 3, e1918962	10.4	81
176	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e012797	6	12
175	Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2020 , 5, 136-145	16.2	14
174	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020 , 141, 352-361	16.7	145
173	Transforming the interpretation of significance in heart failure trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 177-180	12.3	1
172	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 245-254	15.1	41
171	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020 , 5, 336-339	16.2	10
170	Gender differences in industry payments among cardiologists. <i>American Heart Journal</i> , 2020 , 223, 123-131	19	5
169	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	7.9	18
168	Sacubitril/Valsartan: Nephilysin Inhibition 5 Years After PARADIGM-HF. <i>JACC: Heart Failure</i> , 2020 , 8, 800-810	10	24
167	Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. <i>Heart Failure Clinics</i> , 2020 , 16, 433-440	3.3	1

166	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. <i>Current Diabetes Reports</i> , 2020 , 20, 63	5.6	3
165	Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020 , 128, 113-119	3	
164	Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2368-2378	15.1	16
163	Citizenship Status and Cardiothoracic Organ Transplantation in the United States. <i>Circulation: Heart Failure</i> , 2020 , 13, e007788	7.6	0
162	Angiotensin receptor-neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 1525-1530	12.3	2
161	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. <i>Current Opinion in Cardiology</i> , 2020 , 35, 517-523	2.1	2
160	Extensive Arterial Thrombosis in Covid-19. <i>American Journal of Cardiology</i> , 2020 , 134, 148-149	3	2
159	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , 2020 , 142, 1205-1218	16.7	16
158	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , 2020 , 43, 2684-2690	14.6	3
157	Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016. <i>JAMA Network Open</i> , 2020 , 3, e2022190	10.4	14
156	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	20
155	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 356-363	6.4	10
154	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020 , 180, 141-144	11.5	14
153	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 62-71	4.6	3
152	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. <i>JAMA Cardiology</i> , 2020 ,	16.2	8
151	Clinical Outcomes in Young US Adults Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2020 ,	11.5	89
150	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020 , 7, 3298-3309	3.7	26
149	The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience. <i>Journal of Invasive Cardiology</i> , 2020 , 32, E130-E132	0.7	6

148	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	16.7	28
147	Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. <i>JACC: Heart Failure</i> , 2019 , 7, 169-172	7.9	35
146	Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. <i>American Journal of Medicine</i> , 2019 , 132, 840-846	2.4	11
145	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006125	7.6	10
144	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019 , 40, 3593-3602	9.5	38
143	The rise and fall of aspirin in the primary prevention of cardiovascular disease. <i>Lancet, The</i> , 2019 , 393, 2155-2167	4.0	85
142	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2365-2383	15.1	147
141	Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. <i>Journal of Heart and Lung Transplantation</i> , 2019 , 38, 858-869	5.8	48
140	Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 776-782	6.4	14
139	Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2454-2464	15.1	17
138	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019 , 16, e1002797	11.6	20
137	Association of the New Peer Group-Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Network Open</i> , 2019 , 2, e192987	10.4	29
136	Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1336-1349	15.1	56
135	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	15.1	79
134	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1596-1598	15.1	23
133	Misclassification of Myocardial Injury as Myocardial Infarction: Implications for Assessing Outcomes in Value-Based Programs. <i>JAMA Cardiology</i> , 2019 , 4, 460-464	16.2	45
132	Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1827-1845	15.1	79
131	Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. <i>Clinical Cardiology</i> , 2019 , 42, 592-604	3.3	4

130	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y inhibition from the IABP-SHOCK II trial. <i>Resuscitation</i> , 2019 , 137, 205-212	4	19
129	Organ Donation and Drug Intoxication-Related Deaths in the United States. <i>New England Journal of Medicine</i> , 2019 , 380, 597-599	59.2	9
128	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 1660-1666	3	4
127	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 862-874	7.9	40
126	Application of the HFpEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1288-1291	12.3	11
125	Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?. <i>IJC Heart and Vasculature</i> , 2019 , 24, 100404	2.4	
124	Implications of Specialist Density for Diabetes Care in the United States. <i>JAMA Cardiology</i> , 2019 , 4, 1174-1175	16.7	13
123	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. <i>Circulation</i> , 2019 , 140, 2076-2088	16.7	23
122	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. <i>American Journal of Cardiology</i> , 2019 , 124 Suppl 1, S20-S27	3	20
121	Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. <i>Clinical Cardiology</i> , 2019 , 42, 1140-1146	3.3	2
120	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019 , 42, 2298-2306	14.6	70
119	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019 , 19, 157	5.6	5
118	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 1022-1028	7.9	2
117	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , 2019 , 140, 2108-2118	16.7	13
116	Emerging Trends in Financing of Adult Heart Transplantation in the United States. <i>JACC: Heart Failure</i> , 2019 , 7, 56-62	7.9	8
115	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , 2019 , 7, 1-12	7.9	51
114	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 382-391	3	7
113	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. <i>Hypertension</i> , 2019 , 73, 60-67	7.5	11

112	Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Medicine</i> , 2019 , 132, 733-739	2.4	11
111	Sudden Death in Heart Failure With Preserved Ejection Fraction: A Competing Risks Analysis From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 653-661	7.9	34
110	Expanding the global borders of heart failure: the SHOP and PEOPLE studies. <i>European Heart Journal</i> , 2018 , 39, 1781-1783	9.5	3
109	Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. <i>American Journal of Medicine</i> , 2018 , 131, 956-960	2.4	23
108	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 398-405	6.9	18
107	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , 2018 , 15, 10-16	2.8	5
106	Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. <i>International Journal of Cardiology</i> , 2018 , 252, 214-215	3.2	0
105	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 123-131	2.5	
104	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	7.9	18
103	Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope. <i>American Journal of Medicine</i> , 2018 , 131, e451-e453	2.4	1
102	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2018 , 122, 255-260	3	4
101	Oral Anticoagulation in Patients With Liver Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2162-2175	15.1	83
100	Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. <i>JAMA Cardiology</i> , 2018 , 3, 642-649	16.2	111
99	Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1166-1170	15.1	11
98	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1000-1005	16.2	24
97	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , 2018 , 3, 1011-1019	16.2	79
96	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e267-e268	2.4	
95	Type 2 Myocardial Infarction-Diagnosis, Prognosis, and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 433-434	27.4	41

94	Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2018 , 131, 575-577	2.4	28
93	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018 , 137, 938-947	16.7	8
92	Moving Beyond the Hospital. <i>Circulation</i> , 2018 , 138, 2169-2171	16.7	1
91	Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018 , 6, 975-982	7.9	50
90	Developing evidence-based and accountable health policy in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 1653-1656	12.3	4
89	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018 , 7, e010364	6	13
88	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3370-3372	15.1	61
87	Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. <i>Journal of the American Heart Association</i> , 2018 , 7, e010203	6	20
86	Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era-Reply. <i>JAMA Cardiology</i> , 2018 , 3, 1129	16.2	1
85	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e389-e390	2.4	
84	The Drug-Intoxication Epidemic and Solid-Organ Transplantation. <i>New England Journal of Medicine</i> , 2018 , 378, 1943-1945	59.2	47
83	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e263	2.4	
82	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. <i>JACC: Clinical Electrophysiology</i> , 2018 , 4, 944-954	4.6	4
81	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017 , 230, 301-303	3.2	5
80	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 176-185	15.1	36
79	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 556-569	15.1	135
78	Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. <i>International Journal of Cardiology</i> , 2017 , 241, 423-429	3.2	6
77	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 682-685	12.3	23

76	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. <i>JAMA Cardiology</i> , 2017 , 2, 127-135	16.2	30
75	Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 463-464	15.1	15
74	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 552-562	12.3	19
73	Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017 , 120, 359-361	3	9
72	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). <i>American Journal of Cardiology</i> , 2017 , 120, 1043-1048	3	9
71	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. <i>Current Heart Failure Reports</i> , 2017 , 14, 203-209	2.8	1
70	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	26
69	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. <i>Circulation: Heart Failure</i> , 2017 , 10,	7.6	12
68	Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. <i>European Journal of Preventive Cardiology</i> , 2017 , 24, 1648-1659	3.9	13
67	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 122-129	4.2	18
66	Angiotensin-Nepriylsin Inhibition as a Paradigm for All?. <i>Current Cardiology Reports</i> , 2016 , 18, 115	4.2	9
65	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	9
64	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016 , 21, 455-62	5	21
63	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1144-50	3	16
62	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016 , 117, 1845-50	3	8
61	Trends in Heart Failure Clinical Trials From 2001-2012. <i>Journal of Cardiac Failure</i> , 2016 , 22, 171-9	3.3	13
60	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM10) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , 2016 , 117, 1231-5	3	28
59	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016 , 117, 340-6	3	12

58	Coronary stenting approaches in the treatment of chronic total occlusion: contemporary registry-based experience. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 673-9	1.9	1
57	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. <i>European Journal of Heart Failure</i> , 2016 , 18, 128-32	12.3	6
56	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016 , 214, 16-8	3.2	2
55	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1661-71	15.1	52
54	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016 , 129, 1002-5	2.4	24
53	Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	8
52	One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). <i>American Journal of Cardiology</i> , 2016 , 118, 1111-1116	3	2
51	Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. <i>Circulation: Heart Failure</i> , 2015 , 8, 826-31	7.6	28
50	IMAGES IN CLINICAL MEDICINE. Ping-Pong Gaze. <i>New England Journal of Medicine</i> , 2015 , 372, e34	59.2	3
49	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 799-809	2.5	10
48	Prognostic scores in heart failure - Critical appraisal and practical use. <i>International Journal of Cardiology</i> , 2015 , 188, 1-9	3.2	33
47	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. <i>Heart Failure Reviews</i> , 2015 , 20, 393-400	5	3
46	Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. <i>Heart Failure Clinics</i> , 2015 , 11, 591-601	3.3	2
45	Roadmap to inpatient heart failure management. <i>Journal of Cardiology</i> , 2015 , 65, 26-31	3	3
44	A triad of linezolid toxicity: hypoglycemia, lactic acidosis, and acute pancreatitis. <i>Baylor University Medical Center Proceedings</i> , 2015 , 28, 466-8	0.6	13
43	Metastatic pancreatic neuroendocrine tumor with ectopic adrenocorticotrophic hormone production. <i>Baylor University Medical Center Proceedings</i> , 2015 , 28, 46-9	0.6	3
42	Large-volume barium aspiration. <i>Baylor University Medical Center Proceedings</i> , 2015 , 28, 183-4	0.6	6
41	Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). <i>American Journal of Cardiology</i> , 2015 , 116, 307-12	3	2

40	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6 ³		28
39	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , 2015 , 12, 220-9	14.8	129
38	Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 211-7	5.1	17
37	Lipids, statins, and clinical outcomes in heart failure: rethinking the data. <i>Heart Failure Reviews</i> , 2014 , 19, 695-8	5	4
36	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1	1160
35	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1713-21	3	35
34	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 401-8	7.6	27
33	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 743-50	3	8
32	Aspirin Resistance 2014 , 277-284		
31	The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1823-32	15.1	67
30	Death due to munchausen syndrome: a case of idiopathic recurrent right ventricular failure and a review of the literature. <i>Psychosomatics</i> , 2014 , 55, 668-72	2.6	10
29	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9	25
28	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. <i>Heart Failure Reviews</i> , 2014 , 19, 135-52	5	39
27	Sudden flare of rheumatoid arthritis associated with newly diagnosed atrial flutter. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 233-4	0.6	
26	Acute lymphocytic leukemia with superimposed invasive aspergillosis and pneumopericardium successfully treated with voriconazole. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 250-2	0.6	
25	Torus palatinus. <i>Baylor University Medical Center Proceedings</i> , 2014 , 27, 259	0.6	0
24	Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 1153-62	3.9	15
23	Hemoconcentration-guided diuresis in heart failure. <i>American Journal of Medicine</i> , 2014 , 127, 1154-9	2.4	32

22	Dual antiplatelet therapy after stent implantation. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1446	27.4	1
21	Modern drug development: which patients should come first?. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 312, 2619-20	27.4	5
20	Influence of chronic kidney disease on warfarin therapy for atrial fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 2541-2	27.4	
19	In reply to Loh and Lin. <i>Academic Medicine</i> , 2014 , 89, 530	3.9	1
18	Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?. <i>American Journal of Medicine</i> , 2014 , 127, 574-8	2.4	2
17	Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 513-7	15.1	66
16	Rehospitalization for heart failure: problems and perspectives. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 391-403	15.1	434
15	The immunological axis in heart failure: importance of the leukocyte differential. <i>Heart Failure Reviews</i> , 2013 , 18, 835-45	5	40
14	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , 2013 , 1, 488-96	7.9	49
13	Epidemiology of hospitalized heart failure: differences and similarities between patients with reduced versus preserved ejection fraction. <i>Heart Failure Clinics</i> , 2013 , 9, 271-6, v	3.3	11
12	Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 571-9	15.1	47
11	Classification of patients hospitalized for heart failure. <i>Heart Failure Clinics</i> , 2013 , 9, 277-83, v	3.3	2
10	Drug therapy to reduce early readmission risk in heart failure: ready for prime time?. <i>JACC: Heart Failure</i> , 2013 , 1, 361-364	7.9	8
9	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2013 , 112, 1763-9	3	6
8	Expanding the scope of the "polypill" to heart failure. <i>Journal of Cardiac Failure</i> , 2013 , 19, 540-1	3.3	5
7	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013 , 18, 797-813	3.13	22
6	The disconnect between phase II and phase III trials of drugs for heart failure. <i>Nature Reviews Cardiology</i> , 2013 , 10, 85-97	14.8	61
5	Thirty-day readmissions: the clock is ticking. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 345-6	27.4	87

4	Midterm benefits of preoperative statin therapy in patients undergoing isolated valve surgery. <i>Annals of Thoracic Surgery</i> , 2012 , 93, 1881-7	2.7	9
3	Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 750-8	7.6	62
2	Relation of body mass index to late survival after valvular heart surgery. <i>American Journal of Cardiology</i> , 2012 , 110, 1667-78	3	36
1	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 415-22	1.9	26